Kosa Sarah Daisy, Monize Jillian, Leenus Alvin, Leenus Selvin, Samra Simranjit, Szwiega Sylwia, Shi Daniel, Valvasori Sara, Gafni Amiram, Lok Charmaine E, Thabane Lehana
Kidney CARE Network International, Toronto, Ontario Canada.
2Division of Nephrology, Toronto General Hospital, University Health Network, 200 Elizabeth Street 8N844, Toronto, Ontario M5G 2C4 Canada.
Pilot Feasibility Stud. 2019 Apr 6;5:53. doi: 10.1186/s40814-019-0436-3. eCollection 2019.
The conduct of high-quality pilot studies can help inform the success of larger clinical trials. Guidelines have been recently developed for the reporting of pilot trials.
This methodological survey evaluates the completeness of reporting in pilot randomized controlled trials in chronic kidney disease patients on hemodialysis (HD patients) and explores factors associated with better completion of reporting.
The authors searched Pubmed on July 1, 2018, for all pilot trials conducted in HD patients. Reporting quality was assessed against the 40-item Consolidated Standards of Reporting Trials (CONSORT) Extension for Pilot Trials. Study factors including year and country of publication, intervention, number of centers, type of funding, and journal endorsement of CONSORT were also examined.
The mean number of items reported from the CONSORT extension for pilot trials across all included articles was 18.4 (standard deviation [SD] = 4.4). In the adjusted analysis, studies reported in later years (IRR = 1.026, 95% CI [1.018, 1.034], < 0.001) and an increase of 20 persons in sample size (adjusted IRR = 1.021, 95% CI [1.010, 1.031], < 0.001) were associated with a significantly higher number of CONSORT pilot items reported.
Current reporting completeness of pilot trials in HD patients is suboptimal. Endorsing the CONSORT extension specific to pilot and feasibility studies and ensuring that pilot trials focus on the feasibility objectives may improve reporting completeness of these trials.
开展高质量的预试验有助于为大型临床试验的成功提供信息。最近已制定了预试验报告指南。
本方法学调查评估慢性肾病血液透析患者(HD患者)预试验随机对照试验报告的完整性,并探讨与更好完成报告相关的因素。
作者于2018年7月1日在PubMed上检索了所有在HD患者中进行的预试验。根据针对预试验的40项《试验报告统一标准》(CONSORT)扩展版评估报告质量。还检查了研究因素,包括发表年份和国家、干预措施、中心数量、资金类型以及期刊对CONSORT的认可情况。
所有纳入文章中,预试验CONSORT扩展版报告的平均项目数为18.4(标准差[SD]=4.4)。在调整分析中,较晚年份发表的研究(发病率比值比[IRR]=1.026,95%置信区间[CI][1.018,1.034],P<0.001)以及样本量增加20人(调整后的IRR=1.021,95%CI[1.010,1.031],P<0.001)与报告的CONSORT预试验项目数量显著增加相关。
目前HD患者预试验的报告完整性欠佳。认可针对预试验和可行性研究的CONSORT扩展版,并确保预试验专注于可行性目标,可能会提高这些试验的报告完整性。